Factive Reports From BioPortfolio:

Market Research Reports / Management Reports / Research Reports

Results from other life science and pharmaceutical sites:

{1} Release: FACTIVE, Gemifloxacin Mesylate, Tablets Receive ...
(Nasdaq: GENE - News) has received marketing approval for FACTIVE® .... 99.1 to the Company's Annual Report on Form 10-K for the year ending December 31, ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1542292...

News: New Treatment Guidelines for Community-Acquired Pneumonia ...
22 Feb 2007 ... FACTIVE is approved in the U.S. for the seven-day treatment of mild to moderate ... biopharmaceutical company marketing two FDA-approved products with its ...
Roche Reports Positive Data from Five Phase III Trials of Type 2 Diabetes
Therapy ... Tulane Scores $15M to Bolster Research on Lassa Fever ...
http://www.genengnews.com/news/bnitem.aspx?name=13223926...

Oscient Pharmaceuticals Corporation Files for Bankruptcy; Sell its ...
14 Jul 2009 ... Research Store ... According to a Datamonitor report, there is an increased trend in prescribing the fluoroquinolone ... Factive was launched in the U.S. in
September of 2004 and is the only fluoroquinolone ... our ability to maintain
regulatory approvals to market and sell our products that do have ...
http://www.biospace.com/news_story.aspx?NewsEntityId=149893...

GlaxoSmithKline - Annual Report 2000 - Research and development
Factive, broad spectrum fluoroquinolone antibiotic, respiratory tract infections ..... from discovery to development and from development to the market. ...
http://www.gsk.com/financial/reports/ar/report/descrip_of_bu...

Discovery of gemifloxacin (Factive, LB20304a): a quinolone of a ...
Discovery of gemifloxacin (Factive, LB20304a): a quinolone of a new generation. Hong CY. Life Science Research Institute, LG Chem Research Park, Tae-Jon, ...
http://www.ncbi.nlm.nih.gov/pubmed/11347965...

Quick Minutes
Center for Drug Evaluation and Research. 5630 Fishers Lane, Room 1066, Rockville , ... The committee discussed the Factive (gemifloxacin mesylate) Supplemental
New Drug ... The following is an internal report which has not been reviewed.
... Review of post marketing safety of. Andrew Mosholder, M.D., M.P.H.. Factive
...
http://www.fda.gov/ohrms/DOCKETS/ac/06/minutes/2006-4232m1.p...

Bronchitis - BioSpace offers Pharmaceutical, Biotechnology and ...
Genome Therapeutics (GENE) Release: FACTIVE, Gemifloxacin Mesylate, Tablets Receive Marketing Approval From Health Canada 3/11/2004 More. ...
http://www.biospace.com/news_by_disease_results.aspx?TheRxId...

Summary of CORNERSTONE THERAPEUTICS INC - Yahoo! Finance
Financial Statements" of this quarterly report on Form 10-Q and the consolidated ... We began earning revenues from FACTIVE in September 2009; however, our
marketing ..... and consulting expenses relating to increased market research.
...
http://biz.yahoo.com/e/091104/crtx10-q.html...

Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 ...
Successful integration of Curosurf® and relaunch of Factive® expanding our base of ... Sales and marketing expenses increased $10.6 million for the 12 months
ended ... Research and development expenses increased $0.5 million, or 12%, ...
http://www.prnewswire.com/news-releases/cornerstone-therapeu...

Food and Drug Administration
Center for Drug Evaluation and Research (CDER) ... The committee will discuss the Factive (gemifloxacin mesylate) Supplemental New Drug Application 21-158/S-
006, ... post marketing safety. Division of Special Pathogen and ...
http://www.fda.gov/OHRMS/DOCKETS/AC/06/agenda/2006-4232A1-dr...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.